Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-015265
Filing Date
2025-06-16
Accepted
2025-06-16 16:34:51
Documents
63
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1558556
2 EX-31.1 ex31-1.htm EX-31.1 18926
3 EX-31.2 ex31-2.htm EX-31.2 18814
4 EX-32.1 ex32-1.htm EX-32.1 7078
5 EX-32.2 ex32-2.htm EX-32.2 6986
6 GRAPHIC form10-q_001.jpg GRAPHIC 107803
7 GRAPHIC form10-q_002.jpg GRAPHIC 100055
  Complete submission text file 0001641172-25-015265.txt   7889599

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE bctx-20250430.xsd EX-101.SCH 43503
9 XBRL CALCULATION FILE bctx-20250430_cal.xml EX-101.CAL 41204
10 XBRL DEFINITION FILE bctx-20250430_def.xml EX-101.DEF 243683
11 XBRL LABEL FILE bctx-20250430_lab.xml EX-101.LAB 343052
12 XBRL PRESENTATION FILE bctx-20250430_pre.xml EX-101.PRE 290073
65 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1557353
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 001-40101 | Film No.: 251050674
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)